Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: Five-year results with epirubicin and ifosfamide

A. Ottaiano, A. De Chiara, F. Fazioli, V. De Rosa, V. Ravo, V. Boccia, G. Botti, A. Petrillo, F. Fiore, S. Mori, N. Mozzillo, V. R. Iaffaioli, G. Apice

Research output: Contribution to journalArticle

Abstract

Background: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved. Patients and Methods: Twenty-one patients with intermediate/high-grade STS and tumor size ≥5cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m 2/day days 1 and 2 and ifosfamide 1.8 gr/m 2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria. Results: Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery. Conclusion: This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.

Original languageEnglish
Pages (from-to)3555-3559
Number of pages5
JournalAnticancer Research
Volume22
Issue number6 B
Publication statusPublished - Nov 2002

Keywords

  • Epirubicin
  • Ifosfamide
  • Neoadjuvant chemotherapy
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: Five-year results with epirubicin and ifosfamide'. Together they form a unique fingerprint.

Cite this